In their recent article, Stopeck et al. [1] concluded that denosumab confirms its known safety profile even after longterm exposure, or after switching to it from zoledronic acid, and that osteonecrosis of jaws (ONJ) rates increased with increasing exposure to antiresorptives, consistent with previous reports. This is based on the open label extension phase of two phase 3 studies in patients with breast and prostate cancer with bone metastases who were randomized to receive denosumab or zoledronic acid (ZA) [2, 3] . The patients were offered open-label denosumab for up to an additional 2 years after the results of the primary analysis, favorable for denosumab on several aspects. Patients initially randomized to denosumab (denosumab/ denosumab group) continued to receive denosumab at 120 mg Q4W whereas patients on ZA were switched to denosumab in the open-label phase (ZA/denosumab group) at 120 mg Q4W starting 4 weeks from their last ZA dose. Patients who declined further therapy in the open-label extension phase, or who did not complete the blinded treatment phase, continued follow-up for survival every 12 weeks (Q12W) for up to 2 years after their last dose.
To the Editor,
In their recent article, Stopeck et al. [1] concluded that denosumab confirms its known safety profile even after longterm exposure, or after switching to it from zoledronic acid, and that osteonecrosis of jaws (ONJ) rates increased with increasing exposure to antiresorptives, consistent with previous reports. This is based on the open label extension phase of two phase 3 studies in patients with breast and prostate cancer with bone metastases who were randomized to receive denosumab or zoledronic acid (ZA) [2, 3] . The patients were offered open-label denosumab for up to an additional 2 years after the results of the primary analysis, favorable for denosumab on several aspects. Patients initially randomized to denosumab (denosumab/ denosumab group) continued to receive denosumab at 120 mg Q4W whereas patients on ZA were switched to denosumab in the open-label phase (ZA/denosumab group) at 120 mg Q4W starting 4 weeks from their last ZA dose. Patients who declined further therapy in the open-label extension phase, or who did not complete the blinded treatment phase, continued follow-up for survival every 12 weeks (Q12W) for up to 2 years after their last dose.
We collected data from the text and the tables of the paper published by Stopeck et al. [1] and summarized them in a new table (Table 1) .
Although authors' conclusions are quite reassuring both in terms of denosumab safety and efficacy, it is noteworthy that the median exposure of patients to denosumab in the extension phase study is lower than expected, even in the presence of a longer range. The final median exposure of the 318 denosumab/denosumab breast cancer patients is 19.1 months (range 0.1-59.8), not much longer than that registered for the whole cohort of the 1019 breast cancer patient population enrolled in the blinded phase, that was 17.6 months (range 0-23.7). As far as prostate cancer patients are concerned, the median denosumab exposure was 12.0 months (range 0.1-67.2) for the 147 denosumab/denosumab patients from the extension study versus 12.0 months (range 0.1-23.3) for the 942 patients enrolled in the original randomized trial. We could not work out from the paper the median denosumab exposure for 318 breast and 147 prostate cancer patients of the extension study denosumab/denosumab population in the previous blinded phase. This appears to us a weakness of the article.
Interestingly, the frequency of ONJ cases in the open label extension study appears substantially higher than what is found in the initial blinded phase (ONJ frequency ranging from 1 to 2 %) [2, 3] despite median denosumab exposure was not significantly longer in the former. The crude ONJ figures increased both in denosumab/denosumab groups and in ZA/denosumab populations: ONJ cases were respectively 20/318 (6.3 %) in breast patients and 12/147 (8.2 %) in prostate patients in the denosumab/denosumab group, whereas they were 18/334 (5.4 %) breast patients and 7/118 (5.9 %) prostate patients in the ZA/denosumab group.
Such an increase in ONJ frequency highlights the need for longer patients' monitoring and the adoption of nonparametric actuarial estimation (Kaplan-Meier), as done in other studies [10] the integrated analysis of the results of three pivotal trials of blinded comparison between denosumab and zoledronic acid: they also reported the number of Bpotential ONJ^cases that were initially registered as spontaneously reported by investigators or on the base of 36 MedDRA (Medical Dictionary for Regulatory Activities) adverse oral event terms. BPotential ONJ^cases, defined by the presence of clinical sign and symptoms suggestive of ONJ, were three times higher than the finally Badjudicated ONJ^cases: 276/5723 (4.8 %) versus 89/5723 (1.5 %). Of importance, such data were recorded after a relatively short observation time, being the median (Q1, Q3) time on study 12.1 (5.4, 19.4) months for patients in the ZA group and 12.6 (5.6, 19.4) months for patients in the denosumab group [10] . We believe that it would be of great value if the authors of the extension study [1] could report the number of Bpotential ONJ^cases (defined as above) observed in the breast and prostate cancer population of the extension study, and compare them with those of the blinded study, and those among patients who declined shift to denosumab, if available.
There are two burning aspects that we would like to address: the definition of ONJ and the optimal duration of antiresorptive (bisphosphonates or denosumab) treatment.
The definition of ONJ is highly debated and controversial, with evident consequences on clinical practice, trials, and epidemiological studies. The initial definition of ONJ as proposed and published in 2007 by a Task Force of the American Association of Oral Maxillofacial Surgeons (AAOMS) [11] was based on the presence of exposed bone in the oral cavity lasting at least 8 weeks in patients treated with bisphosphonates who did not receive radiation therapy of the head and neck region. This case definition was adopted to adjudicate ONJ patients in clinical trials on bisphosphonates and denosumab.
In recent years, increasing evidence of symptomatic cases of medication-related jawbone alterations without frank bone exposure has raised skepticism among clinicians who questioned the original BRONJ (Bisphosphonate-Related ONJ) case definition, assuming that it could have contributed to epidemiological estimates being inconsistent because it excluded cases with no obviously exposed bone [12] . In 2009, the AAOMS Task Force updated its recommendations on BRONJ [13] by adding the Bstage 0^to classify patients presenting with a number of oral signs and symptoms other than bone exposure but, unfortunately, they did not modify the 2007 definition. The contradictory nature of the position paper was then underlined by several authors and researchers, claiming for a broader definition to include the Bnon-exposedÔ NJ variant [14, 15] .
Hence, the AAOMS Task Force released in 2014 a third position paper [16] that partially expanded the definition of disease to include cases with Bbone that can be probed through an intraoral or extraoral fistula in the maxillofacial region that has persisted for longer than 8 weeks^and confirmed the existence of a Bstage 0 category^for patients with signs and symptoms other than bone exposure and soft-tissue fistulas (Bnonspecific symptoms or clinical and radiographic abnormalities that might be due to exposure to an antiresorptive agent^) [16] . The original acronym BRONJ (bisphosphonaterelated ONJ) was also implemented to include cases of ONJ that were reported after treatment with antiangiogenic agents and denosumab, so that the terms ONJ and MRONJ (medication-related ONJ) are now more correctly used [16] . The AAOMS experts admitted the risk of underestimation of such a definition based only on two clinical signs (bone exposure and fistula), choosing that risk versus the opposite risk of an eventual overestimation (inducible, according to them, by Bcases with radiographic signs alone^) [16] . Overall, these long-lasting controversies on definition are still likely to cause incorrect estimation of ONJ incidence in clinical studies, as well as patient selection and a too-short follow-up duration [17] . On the other hand, an overly restricted ONJ definition might result in late diagnosis of ONJ in clinical practice, exposing patients to rare but life-threatening complications [18, 19] .
The optimal duration of bone metastatic treatment with antiresorptive drugs (i.e., bisphosphonates and denosumab) is yet to be defined.
Most guidelines recommended the long-lasting administration of antiresorptives (that is, till to deterioration of patient general conditions) based on the substantial lack of demonstrated serious side effects in published trials [20, 21] . After reporting several cases of renal toxicity and ONJ, especially in patients exposed for longer time, since years 2006-2007 some guidelines indicated treatment with bisphosphonates for 1 or 2 years, and then Btailoring^the therapy, for both myeloma patients [22] [23] [24] and bone metastases of solid tumors [25] . Despite this, the ASCO did not change recommendations for bone metastatic breast cancers till 2011, after approval of denosumab [26] : it was underlined that BThere are no prospective clinical RCT data to support the continuation of bone-modifying agent therapy beyond 1 year^whereas in the summary table, at the voice BOptimal duration^it was reported BUnchanged in substance from 2003^(that is Bcontinued until evidence of substantial decline in a patient's general performance status.^) [26] .
In conclusion, more data on oral discomfort and more follow-up data from the extension study by Stopeck et al. [1] could be of great value to help patients and prescribers of antiresorptive drugs to share a tailored treatment with the most favorable cost-effectiveness, based on sound evaluation of individual risk factors for safety, together with undeniably favorable effects on skeletal-related effects (SRE) and quality of life.
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